Long non-coding RNAs (lncRNAs) have been demonstrated to be involved in the progression of various cancers. In this study, we aim to investigate the role of lncRNA RUNX1-IT1 in the development of colorectal cancer (CRC). The expression levels of lncRNA RUNX1-IT1 were measured using quantitative real-time Polymerase Chain Reaction(qRT-PCR). CCK8 proliferation assay, transwell assay, and flow cytometry were performed to evaluate the effect of lncRNA RUNX1-IT1 on CRC cell proliferation, migration, and apoptosis. The proliferation markers (PCNA, Ki67), apoptosis markers (cleaved-PARP, cleaved-caspase3), and MMP9 are detected by western blotting. Significant down regulation of lncRNA RUNX1-IT1 was measured in CRC tissues and three CRC cell lines (HCT116, HT29, and RKO) compared with paired nontumorous adjacent tissues (P < 0.01) or the normal colonic epithelial cell line FHC (P < 0.05), respectively. Moreover, the proliferative and migration potential of CRC cells were inhibited by overexpressing lncRNA RUNX1-IT1, which could be obviously improved by knocking down lncRNA RUNX1-IT1. The protein levels of PCNA, Ki67, and MMP9 were upregulated by overexpressing lncRNA RUNX1-IT1 and down regulated in si-RUNX1-IT1 cells.
Long non-coding RNAs (lncRNAs), one category of non-coding RNAs, are more than 200 nucleotides in length and retain little potential to encode proteins. 4 LncRNAs make up 80% of non-scoding RNAs and have been identified to act as regulatory non-coding RNAs in many important biological processes. [4] [5] [6] For example, lncRNA CASC11
is up regulated in CRC and promotes growth and metastasis by interacting with hnRNP-K. 7 Likewise, lnc-GNAT1-1 is negatively associated with proliferation and metastasis processes in CRC. 8 Many other important lncRNAs have also been confirmed to regulate growth and metastasis and influence the prognosis of CRC, such as lncRNA H19, lncRNA HOTAIR, lncRNA-NNT-AS1, lncRNA LINC01133, and lncRNA CCAT1 etc. [9] [10] [11] [12] [13] Runt domain transcription factor (RUNX) family is mainly composed of RUNX1, RUNX2, RUNX, 14 and the functions of these three factors are slightly different. It has been widely accepted that RUNX1 plays a vital role in haematopoiesis and haematopoietic function. 15 Besides, RUNX1 has also been reported as a tumour suppressor in many cancers, such as gastric cancer, lung adenocarcinomas. [16] [17] [18] LncRNA RUNX1-IT1 is the intronic transcript 1 of the RUNX1, which is also known as chromosome 21 open reading frame 96 (C21orF96).
Although the functions of the RUNX1 have been identified in different diseases, the function of the lncRNA RUNX1-IT1 still remains to be elucidated. Besides, no study focusing on the function of lncRNA RUNX1-IT1 has been published in colorectal cancer until now. In our investigation, we aim to study the expression level of lncRNA RUNX1-IT1 in CRC tissues and cell lines. Besides, we also explored its biological roles in the processes of colorectal cancer cell proliferation and migration.
| MATERIAL AND METHODS

| Clinical tissues samples
The clinical CRC tissues paired with nontumorous adjacent tissues 
| Cell culture
Five human CRC cell lines (HCT116, HT29, RKO, SW620, and SW480) and one normal colonic epithelial cell line (FHC) were purchased from the American Type Culture Collection (Manassas, Virginia). HCT116, HT29, and RKO were cultured in RPMI (Hyclone) medium complemented with 10% fetal bovine serum (FBS) and incubated in a culture environment of 5% CO 2 at 37°C. SW620 and SW480 were cultured in RPMI (Hyclone) medium complemented with 10% fetal bovine serum (FBS) and incubated in a culture environment without CO 2 at 37°C. Stable cell lines were constructed using puromycin (2 μg/ml). The lncRNA RUNX1-IT1 transfected cells were named as the lnc RUNX1-IT1 group, and the control group was named as the LV5 group. 
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| Transfection
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| Cell proliferation assay
The potential for cell proliferation was determined using the cell counting kit 8 (CCK-8, Dojindo with 5% CO 2 , the devices were removed from the bottom chamber and the medium from the upper chamber was discarded. Any nonmigrated cells were scraped off using a cotton bud. Cells that had penetrated through the pores of the membrane were fixed with pure methanol for 1 minute and then treated with haematoxylin for 3 minutes and eosin for 30 seconds. The population of cells that migrated through the inserted filter was counted in 10 randomly and uniformly selected visual fields of the membrane by an inverted microscope (Leica DMI300B).
| Western blotting
Total protein of the cells was extracted following the manufacturer's protocol of Total Protein Extraction kit (KeyGen). SDS-PAGE was 
| Flow cytometry
We trypsinized and resuspended the cells to generate single-cell sus- 
| Methods of statistical analysis
Relative RNA expression levels of lncRNA RUNX1-IT1 in CRC tumorous tissues compared with NATs were calculated using −ΔΔCT, the negative difference between the ΔCT values of the tumorous tissues and the NATs (-ΔΔCT = -(ΔCT tumorous lncRNA -ΔCT NATs lncRNA ). ΔCT is the difference between the target cDNA and endogenous reference in the CT value (GAPDH; ΔCT = CT lncRNA -CT GAPDH ). All statistical analyses were performed on SPSS 20.0 computer software (SPSS Inc.). P < 0.05 was considered as statistically significant. The correlation between lncRNA expression and clinicopathological parameters was evaluated by the Mann-Whitney U test for two groups and the Kruskal-Wallis test for three groups. To analyse the overall survival (OS), the KaplanMeier method was used, and the log-rank test was used to compare survival curves. Cut-off scores were selected by evaluating the receiver-operating characteristic curve (ROC curve) for the expression of lncRNA RUNX1-IT1 and the end-point survival. The point on the curve with the shortest distance to the coordinate (0, 1)
was selected as the cut-off value to classify cases as "high expression" or "low expression." 19 The Cox proportional hazards model was also used for the univariate analysis. For all experiments, data from at least three independent experiments are displayed as the mean ± standard deviation (SD). All statistical analyses were conducted using an unpaired two-tailed Student's t test, depending on conditions.
3 | RESULTS
| LncRNA RUNX1-IT1 is downexpressed in two CRC cohorts and CRC cell lines
The expression of lncRNA RUNX1-IT1 was examined in cohort 1, and the significant downexpression of lncRNA RUNX1-IT1 in CRC tissues (85.42%, n = 82) was demonstrated by qRT-PCR compared with NATs ( Figure 1A and 1B). In order to verify the expression result of lncRNA RUNX1-IT1, we also detected the expression level of lncRNA RUNX1-IT1 in another cohort, which included 59 CRC patients underwent curative surgery in recent 2 years. In these 59 Mean of relative expression, with standard deviation. *Indicated statistical significance (P < 0.05).
CRC patients, 88.14% (n = 52) showed a low expression of the lncRNA RUNX1-IT1 in GC tissues compared with NATs ( Figure 1C and 1D), which was similar to the result of cohort 1. We also inves- Table 1 ). The analyse results of cohort 2 were similar to those of cohort 1, and no significant correlation was found between the expression of lncRNA RUNX1-IT1 and clinicopathological features (Table 2) .
| LncRNA RUNX1-IT1 expression level and patient survival
The 87 (9 patients did not have survival data) patients in cohort 1 were divided into two groups, a high-expression group (n = 69) and a lowexpression group (n = 18), based on the cut-off value calculated by evaluating the ROC curve for the expression of lncRNA RUNX1-IT1 and the end-point survival.. According to the Kaplan-Meier curves, we found no significant disparity between the OS of these two groups ( Figure 1F ).
Subsequently, we performed the univariate analysis and found that pN category (P = 0.001) and lymph node metastasis (P = 0.008) were significantly associated with the prognosis of CRC patients. However, the expression of lncRNA RUNX1-IT1 was not obviously related to the overall survival of CRC patients (Table 3) . 
| Diagnostic efficiency of lncRNA RUNX1-IT1
To investigate the diagnostic performance of lncRNA RUNX1-IT1 in CRC, we used the ROC curve. As shown in Figure 2A , the area under the curve (AUC) of the ROC curve of cohort 1 was 0.780, with a sensitivity of 0.740 and specificity of 0.760. In cohort 2, the AUC was 0.774, with a sensitivity of 0.831 and specificity of 0.610 (Figure 2 B). These results indicated that the expression of lncRNA RUNX1-IT1 had a moderate to strong diagnostic efficiency for the CRC cases.
| LncRNA RUNX1-IT1 could inhibit CRC cell proliferation
To study the function of lncRNA RUNX1-IT1 in CRC cells, we selected Figure 3B , the overexpression of lncRNA RUNX1-IT1 could significantly inhibit the proliferation of the lnc RUNX1-IT1 group compared with the LV5 group (P < 0.01). Besides, the proliferation of HCT116 cells and RKO cells were both improved after knocking down the lncRNA RUNX1-IT1( Figure 3C ). Meanwhile, we also detected the expression level of proliferation markers PCNA and Ki67. The western blotting results indicated that PCNA and Ki67 were downregulated in lncRNA RUNX1-IT1 overexpression cells and upregulated in si-RUNX1-IT1 cells ( Figure 3D ). All in all, we proved that lncRNA RUNX1-IT1 could inhibit CRC cells proliferation.
| LncRNA RUNX1-IT1 could inhibit CRC cell migration
We conducted migration assays to investigate the effect lncRNA RUNX1-IT1 may have on the migration of CRC cells. The results
showed that the lnc RUNX1-IT1 group cells were less likely to penetrate the membrane in two CRC cells lines ( Figure 4A , P < 0.01). In contrast, the si-RUNX1-IT1 group cells were more likely to penetrate the membrane compared with si-NC cells ( Figure 4B , P < 0.01). From the western blotting results, we found that MMP9 was also downregulated in lncRNA RUNX1-IT1 overexpression cells and upregulated in si-RUNX1-IT1 cells ( Figure 4C ). These indicates that lncRNA RUNX1-IT1 takes a part in the negative regulation on CRC cell migration.
| LncRNA RUNX1-IT1 could promote CRC cell apoptosis
To illuminate the potential regulatory mechanism of lncRNA RUNX1- 
| DISCUSSION
Known as one of the top life-threatening cancers, CRC is also a shockingly common diagnosis among malignancies. In recent years, Until now, only one study has been found reporting the function of lncRNA RUNX1-IT1, which is also known as lncRNA C21orf96.
Yang et al found that lncRNA C21orf96 was highly expressed in positive lymph node tissues and gastric cancer tissues, and it could promote the tubular formation, migration, and invasion of the gastric cancer cells. 23 However, we found that lncRNA RUNX1-IT1 played a tumour suppressive role in CRC. This may result from tumour heterogeneity and individual difference, which may also be found in studies concerning other lncRNAs. For example, Zhang et al found that lncRNA BANCR could promote the cell proliferation in gastric cancer. 24 We would see to it that these assays be held as priorities in our future plan.
| CONCLUSION
In our study, we revealed that lncRNA RUNX1-IT1 was dramatically down regulated in tumorous tissues from CRC patients. We also demonstrated the diagnostic efficiency of lncRNA RUNX1-IT1 and its regulatory roles in CRC cell proliferation, migration, and apoptosis, which indicates that lncRNA RUNX1-IT1 may serve as a potential biomarker and, hopefully, a future therapeutic target for the treatment of CRC.
